NCT01767532View on ClinicalTrials.gov

Bioequivalence Study of Cephalexin Suspension 125

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

January 30, 2011

Primary Completion Date

February 8, 2011

Study Completion Date

February 8, 2011

Conditions
Infections, Respiratory Tract
Interventions
DRUG

Cephalexin 125 mg/5ml

Reference product 20 ml

DRUG

Cephalexin 125 mg/5ml

Test product 20 ml

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01767532 - Bioequivalence Study of Cephalexin Suspension 125 | Biotech Hunter | Biotech Hunter